

PERSONAL INFORMATION

Hafedh Marouani

WORK EXPERIENCE

July 2013–Present

pharmacometrician

ANSM (France)

- Assessment of PK parts of MA dossiers (centralized, DCP/MRP and national procedures)
- Assessment of bioavailability and bioequivalence studies.

December 2012–June 2013

pharmacometrician

Pierre Fabre research institute (France)

- Analysis and interpretation of PK and PK/PD studies in humans
- Drafting of plan analysis and PK reports for clinical studies.

November 2005–May 2011

pharmacist

CHU of Timone Marseille (France)

Hospital Pharmacy, TDM, pharmacokinetics

EDUCATION AND TRAINING

2008–2012

PhD in pharmacometrics

Aix-Marseille university - Faculty of Pharmacy (France)

- Modeling and Pharmacometrics department
- Subject: Estimating Variability in Population Pharmacokinetics with Nonparametric Approach – Drug regimen individualization in clinics using Kinetic Nomograms.

2003–2007

Pharmacy residency program

Hospitals and universities of Tunis, Montpellier and Marseille

- Development and practice of analytical bioassays for drugs (HPLC, immunoanalysis, GC, HPLC-MS/MS)
- Therapeutic Drug Monitoring
- Clinical Pharmacy.

2004–2006

Master's degree in drug development

Faculty of Pharmacy of Montpellier

1997–2002

Pharm.D

Faculty of Pharmacy of Monastir (Tunisia)

ADDITIONAL INFORMATION

Expertise

Modeling and simulation in PK/PD

- Compartmental and non-compartmental analysis
- Population approaches (parametric and non-parametric)
- PK/PD response modeling, simulations and statistics

Clinical pharmacy:

- Therapeutic drug monitoring and Toxicology screening

- Dosage regimen individualization (Bayesian approach, Kinetic-Pro software and Kinetic nomograms)

Hands-on experience on PK/PD and population tools:

- Monolix, Nonmem and Phoenix/WinNonlin software packages
- MATLAB analysis/simulation platform, SAS and R softwares

Publications

1. Progress in strategies for dosage regimen individualization. *Curr. Top. Med. Chem.* 2012 12(16). Marouani H, Woloch C, Frances N, Benay S, Iliadis A.
2. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer Patients. *Curr. Top. Med. Chem.* 2012 12(16). Woloch C, Di Paolo A, Marouani H, Bocci G, Ciccolini J, Iliadis A.
3. Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients. *Curr. Top. Med. Chem.* 2012 12(16). Frances N, Woloch C, Marouani H, Mercier C, Iliadis A.
4. Kinetic nomograms assist individualization of drug regimens. *Clin. Pharmacokinet.* 2011 Dec;50(12):773-9. Marouani H, Zografidis A, Iliadis A.
5. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. *Cancer Chemother Pharmacol.* 2011 Jan;6(1):49-56. Yang CG, Ciccolini J, Blesius A, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C.
6. Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines. *J Chemother.* 2010 Apr;22(2):129-33. Chefrour M, Fischel JL, Formento P, Marouani H, Francoual M, Renée N, Mercier C, Milano G, Ciccolini J.
7. Effects of hyperthermia on pharmacokinetics of ertapenem in rats. *Fundam Clin Pharmacol.* 2008 Jun;22(3):285-9. Boulamery A, Marouani H, Guilhaumou R, Rocher E, Simon N, Bruguerolle B.

In progress

- Dosage regimen individualization of the once-daily amikacin treatment by using kinetics nomograms. Marouani H, Contargyris C, Anastoulos S, Woloch C, Iliadis A.
- Performance evaluation of optimization algorithms used in individual pharmacokinetic modeling. Benay S, Marouani H, Woloch C, Iliadis A.

Projects

Memberships

Other Relevant Information